Premium
Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus‐1 gp41 and equine infectious anemia virus gp45
Author(s) -
Duan Liangwei,
Du Jiansen,
Liu Xinqi
Publication year - 2015
Publication title -
protein science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.353
H-Index - 175
eISSN - 1469-896X
pISSN - 0961-8368
DOI - 10.1002/pro.2750
Subject(s) - equine infectious anemia , immunogen , virology , gp41 , immune system , virus , biology , immunodeficiency , immunology , antibody , epitope , monoclonal antibody
Abstract An effective vaccine against acquired immune deficiency syndrome is still unavailable after dozens of years of striving. The glycoprotein gp41 of human immunodeficiency virus is a good candidate as potential immunogen because of its conservation and relatively low glycosylation. As a reference of human immunodeficiency virus gp41, gp45 from equine infectious anemia virus (EIAV) could be used for comparison because both wild‐type and vaccine strain of EIAV have been extensively studied. From structural studies of these proteins, the conformational changes during viral invasion could be unveiled, and a more effective acquired immune deficiency syndrome vaccine immunogen might be designed based on this information.